Janus Kinase Inhibitor

Phase 3Small molecule

PPeking Union Medical College Hospital

Janus Kinase Inhibitor is one of 54 small molecule programs targeting Bullous Pemphigoid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bullous PemphigoidActive, not recruiting

Ulcerative ColitisActive, not recruiting

Blau SyndromeEnrolling by invitation

Bullous PemphigoidPreclinical

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

Blau SyndromePhase 3

Enrolling by invitation

Competition

Competitive Landscape

104 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Humira

Novartis

Phase 3

19 2

Stelara

Johnson & Johnson

Phase 3

11 3

Velsipity

Pfizer

Phase 3

10 4

Jyseleca

Gilead

Phase 3

6 5

Skyrizi

AbbVie

Phase 3

6 6

Tremfya

Johnson & Johnson

Phase 3

2 7

Mounjaro

Eli Lilly

Phase 3

1 8

Mesalazine

Ferring

Phase 3

17 9

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 10

Jardiance

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Unknown status·ZZhejiang Provincial People's Hospital·Phase 3·NCT05451615·90 enrolled

COVID-191 trial

Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

Terminated·VVanderson Geraldo Rocha·Phase 2/3·NCT04477993·5 enrolled

Blau syndrome1 trial

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

Enrolling by invitation·PPeking Union Medical College Hospital·Phase 4·NCT06660329·30 enrolled

Bullous Pemphigoid1 trial

JAK Inhibitors' Efficacy in Bullous Pemphigoid

Completed·CChao Ji··NCT06561256·120 enrolled

Ulcerative Colitis1 trial

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Terminated·AAlimentiv Inc.··NCT04576000·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Janus Kinase Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Janus Kinase Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Janus Kinase Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking Union Medical College Hospital

Janus Kinase Inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

COVID-191 trial

Blau syndrome1 trial

Bullous Pemphigoid1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News